Bovine-derived lactoferrin antibacterial peptide modified body as well as expression and application thereof in pichia pastoris
By fusing and mutating the gene of lactoferrin antimicrobial peptide in Pichia yeast, antimicrobial activity is improved, the problem of difficulty and high cost of extraction of lactoferrin antimicrobial peptides is solved, and efficient inhibition of Staphylococcus aureus is achieved, providing A potential antibiotic replacement drug.
Patent Information
- Application Number
- CN202410919458.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-01
AI Technical Summary
Lactoferrin antimicrobial peptides face difficulties and high cost in large-scale production and clinical applications, and their antimicrobial effects need to be further improved to adapt to industrial applications.
By fusing the antimicrobial peptide Lactoferricin with LF1-11 and Lactoferrampin or performing amino acid sequence mutations and recombinant expression in Pichia cerevisiae, a highly expressed recombinant Pichia strain is constructed to improve antibacterial activity.
An antimicrobial peptide modification with a 149% increase in Staphylococcus aureus was obtained, providing a safe, green and efficient antimicrobial alternative with broad application prospects.
Smart Images

Figure CN118878701A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bioengineering, and in particular to a modified bovine lactoferrin antimicrobial peptide and its expression and application in Pichia pastoris. Background Art
[0002] Lactoferrin is a rich source of cationic and hydrophobic antimicrobial peptides, which are part of the lactoferrin polypeptide chain and are released when various proteolytic enzymes proteolyze the molecule. They can be developed into clinically useful antimicrobial therapeutic lead molecules. Lactoferrin peptides are produced by proteolysis of lactoferrin. There are three main types reported in detail, including LF1-11, Lactoferrampin and Lactoferricin. LF1-11 consists of the first 11 residues at the N-terminus of lactoferrin, Lactoferrampin consists of residues 268-284 of lactoferrin, and Lactoferricin consists of residues 17-41 of lactoferrin. The net positive charge enables them to effectively interact with the negatively charged bacterial cell membrane, destroying the integrity of the membrane and achieving a bactericidal effect. In 1992, the first report on lactoferrin described that the peptide was more effective as an antimicrobial agent than intact lactoferrin and was shown to cause a rapid loss of colony-forming ability for most of its targets. In addition to its broad-spectrum antimicrobial activity, lactoferrin antimicrobial peptides also have antiviral, antiprotozoal, tumor suppressor and apoptosis inducing activities.
[0003] Although lactoferrin antimicrobial peptides have many advantages and broad application prospects, their large-scale production and clinical application still face some challenges. At present, lactoferrin antimicrobial peptides are mainly obtained by enzymatic hydrolysis of lactoferrin, but lactoferrin itself is difficult to extract and expensive. Lactoferrin is mainly found in the milk of mammals, especially in cow's milk, but its content is relatively low. The extraction of lactoferrin requires a complex process, including multiple steps such as pretreatment, separation, and purification of milk, which have high requirements for technology and equipment. During the extraction process, it is necessary to ensure that the activity of lactoferrin is not destroyed, which further increases the difficulty of extraction. The antimicrobial peptides obtained by recombinant expression in microbial cells have attracted widespread attention due to their low production cost and simple preparation process. For example, Li et al. trnQ By driving the expression of six tandem repeat sequences, recombinant expression of lactoferrin was achieved in Bacillus subtilis.
[0004] Although lactoferrin peptide has shown certain antibacterial activity, its antibacterial effect still needs to be further improved in practical applications. Improving the antibacterial activity of lactoferrin peptide is a complex issue involving multiple aspects. If the antibacterial activity can be improved through genetic engineering, the quality of antibacterial peptide can be further improved, which will be of great significance for the industrial application of bovine lactoferrin antibacterial peptide. Summary of the invention
[0005] In order to solve the above technical problems, the present invention is based on the bovine lactoferricin antimicrobial peptide Lactoferricin for transformation, the transformation includes fusion expression of bovine lactoferricin antimicrobial peptide Lactoferricin with bovine lactoferricin antimicrobial peptide LF1-11 and Lactoferrampin, or mutating the 4th arginine, the 5th arginine, the 8th tryptophan, the 9th arginine, the 11th lysine, the 14th glycine or a combination thereof of the starting sequence of Lactoferricin as shown in SEQ ID NO.6, and performing recombinant expression in Pichia pastoris.
[0006] The first object of the present invention is to provide an antimicrobial peptide modification, wherein the antimicrobial peptide modification is obtained by modifying bovine lactoferricin antimicrobial peptide Lactoferricin, wherein the modification comprises fusion expression of bovine lactoferricin antimicrobial peptide Lactoferricin with bovine lactoferricin antimicrobial peptide LF1-11 and Lactoferrampin, or mutation of bovine lactoferricin antimicrobial peptide Lactoferricin, wherein the mutant has any of the following mutations relative to the amino acid sequence shown in SEQ ID NO.6:
[0007] (1) Arginine at position 4 mutated to glycine, arginine at position 5 mutated to threonine, and arginine at position 9 mutated to isoleucine;
[0008] (2) mutation of arginine at position 5 to lysine;
[0009] (3) mutation of glycine at position 14 to arginine;
[0010] (4) The tryptophan at position 8 mutated to arginine, and the lysine at position 11 mutated to tryptophan.
[0011] Furthermore, the fusion is to fuse the bovine lactoferrin antimicrobial peptide Lactoferricin to the N-terminus of the bovine lactoferrin antimicrobial peptide LF1-11, and to fuse the bovine lactoferrin antimicrobial peptide Lactoferrampin to the C-terminus of the bovine lactoferrin antimicrobial peptide LF1-11.
[0012] The second object of the present invention is to provide a gene encoding the above antimicrobial peptide modification.
[0013] Furthermore, the nucleotide sequence encoding the modified antimicrobial peptide Lactoferricin-LF1-11-Lactoferrampin is shown in SEQ ID NO. 1. The third object of the present invention is to provide a recombinant Pichia pastoris, wherein the modified antimicrobial peptide is heterologously expressed in a Pichia pastoris host strain to obtain the recombinant Pichia pastoris.
[0014] Furthermore, the Pichia pastoris host bacteria include Pichia pastoris X-33, Pichia pastoris GS115, Pichia pastoris SMD1168 or Pichia pastoris SMD1163.
[0015] Preferably, the Pichia pastoris host strain is Pichia pastoris X-33.
[0016] Furthermore, the recombinant Pichia pastoris uses pPICZaA as a plasmid vector to recombinantly express the antimicrobial peptide modification.
[0017] Furthermore, a purification tag is provided on the antimicrobial peptide modification expression frame.
[0018] Furthermore, the purification tag is a 6×His tag.
[0019] Furthermore, the expression product of the recombinant Pichia pastoris was purified using a nickel column.
[0020] Furthermore, the nucleotide sequence of the purification tag is shown in SEQ ID NO.3, and the amino acid sequence is shown in SEQ ID NO.4.
[0021] Furthermore, an inducible promoter is used for expression.
[0022] Furthermore, the inducible promoter includes P AOX1 Promoter.
[0023] Furthermore, the antimicrobial peptide modification is secreted under the guidance of the signal peptide 0030-α, and the nucleotide sequence of the signal peptide 0030-α is shown in SEQ ID NO.5.
[0024] The fourth object of the present invention is to provide a method for producing modified antimicrobial peptides, comprising the step of fermentation production using the above-mentioned recombinant Pichia pastoris.
[0025] Furthermore, the recombinant Pichia pastoris is inoculated into a fermentation medium for fermentation culture to obtain a fermentation broth, the bacterial cells are collected and washed, and then inoculated into an induction medium for induced expression of the antimicrobial peptide transformant.
[0026] Furthermore, an inducer is added during the induction expression process, and the final concentration of the inducer is 0.8-1.2%.
[0027] Furthermore, the fermentation medium includes 18-22 g / L of peptone, 8-12 g / L of yeast powder, 8-12 mL / L of glycerol, 10-15 g / L of YNB, 3-5×10 -4 g / L, potassium phosphate buffer 80-120mM.
[0028] Furthermore, the induction medium includes 18-22 g / L of peptone, 8-12 g / L of yeast powder, 4-7 mL / L of methanol, 10-15 g / L of YNB, 3-5×10 -4 g / L, potassium phosphate buffer 80-120mM.
[0029] The fifth object of the present invention is to provide the use of the above-mentioned antimicrobial peptide modification or the above-mentioned recombinant Pichia pastoris in the preparation of a product with activity to inhibit Staphylococcus aureus.
[0030] Beneficial effects of the present invention:
[0031] The present invention is based on the bovine lactoferricin antimicrobial peptide Lactoferricin, and by fusion expression of Lactoferricin, LF1-11 and Lactoferrampi, or by mutation of the amino acid sequence of Lactoferricin, the fusion antimicrobial peptide Lactoferricin-LF1-11-Lactoferrampin and the mutant peptide LFT3 with the highest antibacterial activity against Staphylococcus aureus are screened, and a recombinant Pichia pastoris X-33 strain capable of efficiently expressing two novel antimicrobial peptides is constructed, which can be used for fermentation production of antimicrobial peptide modified bodies, and the antimicrobial activity of the mutant peptide LFT3 obtained by fermentation is 149% of that of the mother peptide Lactoferricin. The antimicrobial peptide modified bodies Lactoferricin-LF1-11-Lactoferrampin and LFT3 provided by the present invention are expected to replace antibiotics to become a safe, green, efficient and ideal antimicrobial agent, and can be used as a potential antibiotic substitute, with very broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein
[0033] Figure 1 In Example 1 of the present invention, the antimicrobial peptides LF1-11, Lactoferricin and Lactoferrampin derived from bovine lactoferrin are arranged and combined to obtain six fusion antimicrobial peptides;
[0034] Figure 2This is a schematic diagram of the construction of the Lactoferricin-LF1-11-Lactoferrampin plasmid in Example 1 of the present invention;
[0035] Figure 3 The OD of the recombinant strain detected by the microplate reader in Example 3 of the present invention 600 Absorbance value and green fluorescence absorbance value result graph;
[0036] Figure 4 This is the result of rescreening the mutant strain in Example 3 of the present invention, where the red one is the fermentation product of X-33-Lactoferricin, and the rest are the fermentation products of the mutant strain;
[0037] Figure 5 is the antibacterial comparison between the fusion peptide and bovine lactoferricin peptide Lactoferricin in Example 6 of the present invention, wherein 1 is the fermentation product of X-33-LF1-11-Lactoferricin-Lactoferrampin, 2 is the fermentation product of X-33-LF 1-11-Lactoferrampin-Lactoferricin, 3 is the fermentation product of X-33-Lactoferricin-LF1-11-Lactoferrampin, 4 is the fermentation product of X-33-Lactoferricin-Lactoferrampin-LF1-11, 5 is the fermentation product of X-33-Lactoferricin-LF1-11-Lactoferricin, 6 is the fermentation product of X-33-Lactoferrampin-Lactoferricin-LF1-11, and Lactoferricin is the fermentation product of X-33-Lactoferricin;
[0038] Figure 6 This is an antibacterial comparison between the mutant peptide in Example 7 of the present invention and the bovine lactoferricin peptide Lactoferricin, wherein Lactoferricin is the fermentation product of X-33-Lactoferricin, LFT1 is the fermentation product of X-33-LFT1, LFT2 is the fermentation product of X-33-LFT2, LFT3 is the fermentation product of X-33-LFT3, LFT4 is the fermentation product of X-33-LFT4, and X-33 is the fermentation product of X-33-pPICZαA. DETAILED DESCRIPTION
[0039] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0040] (I) Strains and vectors
[0041] The plasmid was constructed in E. coli DH5α, and after the plasmid was constructed, it was transformed into Pichia pastoris for expression and fermentation of lactoferrampin. The vector pPICZaA used was a commercial plasmid.
[0042] (II) Culture medium
[0043] LB medium was used for E. coli DH5α and indicator strain G600-sfGFP, YPD liquid medium and YPD solid medium were used for mutant screening, and fermentation medium was used for recombinant Pichia pastoris for 0-1 days and induction medium for 2-6 days;
[0044] LB medium: tryptone 10 g / L, yeast powder 5 g / L, NaCl 10 g / L;
[0045] YPD liquid medium: peptone 10g / L, yeast powder 20g / L, glucose 20g / L;
[0046] Fermentation medium: peptone 18-22g / L, yeast powder 8-12g / L, glycerol 8-12mL / L, YNB 10-15g / L, biotin 4×10 -4 g / L, potassium phosphate buffer 80-120 mM;
[0047] Induction medium: peptone 18-22g / L, yeast powder 8-12g / L, methanol 4-7mL / L, YNB 10-15g / L, biotin 4×10 -4 g / L, potassium phosphate buffer 80-120mM.
[0048] Example 1: Construction of fusion antimicrobial peptide
[0049] like Figure 1As shown, the fusion peptide is composed of three antimicrobial peptides LF1-11, Lac toferricin and Lactoferrampin derived from bovine lactoferrin, and the combinations thereof are used to obtain six fusion antimicrobial peptides (LF1-11-Lactoferricin-Lactoferrampin, LF1-11-Lactoferrampin-Lactoferricin, Lactoferricin-LF 1-11-Lactoferrampin, Lactoferricin-Lactoferrampin-LF1-11, Lactoferrampin-LF1-11-Lactoferricin, Lactoferrampin-Lactoferricin-LF1-11). Taking the construction of the Lactoferricin-LF1-11-Lactoferrampin plasmid as an example ( Figure 2 ), the constructed fusion peptide expression frame consists of two parts: Lac toferricin-LF1-11-Lactoferrampin gene and 6×His tag. Lactoferricin-LF1-11-Lactoferrampin has been optimized according to the codon preference of Pichia pastoris, and its nucleotide sequence and amino acid sequence are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively. The nucleotide sequence and amino acid sequence of the 6×His tag are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively. The recombinant protein can be purified using a nickel column through the tag. The plasmid vector used is the commercial plasmid pPICZaA, which is a stable high-copy Pichia pastoris expression vector. The promoter of this vector is P AO X1, the signal peptide is 0030-α, and the nucleotide sequence of the signal peptide is shown in SEQ ID NO. 5. Then, the lactoferrampin expression cassette was connected to the plasmid vector to obtain the recombinant plasmids pPICZaA-LF1-11-Lactoferricin-Lactoferrampin, pPICZaA-LF1-11-Lactoferrampin-Lactoferricin, pPICZaA-Lactoferricin-LF1-11-Lactoferrampin, pPICZaA-Lactoferricin-Lactoferra mpin-LF1-11, pPICZaA-Lactoferrampin-LF1-11-Lactoferricin, and pPICZaA-Lact oferrampin-Lactoferricin-LF1-11. The recombinant plasmid was transformed into Pichia pastoris X-33 strain to obtain recombinant strains X-33-LF1-11-Lactoferricin-Lactoferrampin, X-33-LF1-11-Lactoferra mpin-Lactoferricin, X-33-Lactoferricin-LF1-11-Lactoferrampin, X-33-Lactofer ricin-Lactoferrampin-LF1-11, X-33-Lactoferrampin-LF1-11-Lactoferricin, and X-33-Lactoferrampin-Lactoferricin-LF1-11.
[0050] Example 2: Construction of Lactoferricin mutant strain library
[0051] The lactoferricin gene sequence was randomly mutated using the Bio-Tech random mutagenesis kit to obtain an antimicrobial peptide sequence library. The plasmid vector used was the commercial plasmid pPICZaA, the promoter of which was P AOX1 , the signal peptide is 0030-α, and it carries a 6×His tag, through which the recombinant protein can be purified using a nickel column. The antimicrobial peptide library is then connected to a plasmid vector to obtain a recombinant plasmid library. The recombinant plasmid library is electroporated into the Pichia pastoris X-33 strain, and then spread on a YPD plate containing bleomycin resistance to obtain a single colony.
[0052] Example 3: Preliminary screening of mutation library
[0053] The single colony obtained in Example 2 was inoculated into a 96-well plate, and then cultured in YPD medium at 30°C for 1 day. The medium was replaced by YPD+1% methanol by centrifugation to induce expression for 4 days, during which 1% methanol was added every 24 hours to obtain the fermentation product of the recombinant strain library.
[0054] The indicator strain G600-sfGFP (disclosed in CN116515882A) and Staphylococcus aureus were inoculated into a shaking tube containing 2 mL of LB medium and cultured overnight. Then, 160 μL of LB and 40 μL of the fermentation product of the above-mentioned recombinant strain library were added to a 96-well plate, and then 1% of the indicator strain culture was inoculated and cultured at 37°C for 24 hours. The OD values of the indicator strain G600-sfGFP were detected using an ELISA instrument. 600 Absorbance and green fluorescence absorbance, as well as OD of Staphylococcus aureus 600 Absorbance value, the result is Figure 3 As shown. Pick OD 600 The recombinant strains with very low absorbance and green fluorescence absorbance were screened again, cultured in shake flasks and inoculated with indicator strains G600-sfGFP and Staphylococcus aureus, and the OD was detected after repeating the above culture process. 600 Absorbance value, rescreening results see Figure 4 . After the initial screening and re-screening, both the OD 600 The recombinant strains with low absorbance or green fluorescence absorbance were sent to GeneWeichi for sequencing, and the results were consistent. The four mutants obtained are shown in Table 1.
[0055] Table 1 Mutant peptide sequences and charge numbers
[0056]
[0057]
[0058] Example 4: High-efficiency expression of fusion peptides and mutant peptides
[0059] The engineered strains X-33-LF1-11-Lactoferricin-Lactoferrampin, X-33-LF1-11-Lactoferrampin-Lactoferricin, X-33-Lactoferricin-LF1-11-Lactoferrampin, X-33-Lactoferricin-Lactoferrampin-LF1-11, X-33-Lactoferrampin-LF1-11-Lactoferricin, X-33-Lactoferrampin-Lactoferricin-LF1-11 and X-33-LFT1, X-33-LFT2, X-33-LFT3 and X-33-LFT4 obtained in Example 1 and Example 3 were inoculated into a round-bottom test tube containing 2 mL of YPD medium for overnight culture, and 1 mL of the overnight culture solution was inoculated into 25 mL of fermentation medium for shake flask fermentation, and cultured at 30° C. and 220 rpm until OD 600 At about 60, 4°C, 3500g, centrifuge for 10 minutes, collect cells, discard supernatant, and wash twice with sterile water. Centrifuge under the same conditions after each wash and take supernatant. Resuspend cells with induction medium, induce expression at 30°C, 220rpm, add methanol every 24h to a final concentration of 1% (volume concentration). After 5 days of methanol induction culture. Centrifuge and collect supernatant, concentrate by centrifugation, and purify the sample using nickel column.
[0060] Example 5: Fermentation supernatant purification
[0061] The supernatant collected in Example 4 was purified using a Ni smart beads 6FF gravity column (smart-Lifesciences). First, the gravity column was balanced with 10 column volumes of PBS buffer, and then 10 mL of fermentation supernatant was loaded into the pre-balanced gravity column, and then 10 column volumes of washing buffer (PBS containing 5 mM imidazole) were added to rinse the tube wall. After washing, 4 column volumes of elution buffer (PBS containing 250 mM imidazole) were used to elute the target protein, and six tubes were divided for gradient collection, with 1 mL collected in the first tube and the last tube, and 0.5 mL collected in each tube of 2-5. The obtained samples were subjected to SDS-PAGE analysis, and the samples in the collection tube containing the target band and a single band were taken for BCA kit quantitative analysis and antibacterial analysis.
[0062] Example 6: Determination of antibacterial activity of fusion peptides
[0063] The recombinant plasmid was transformed into the X-33 strain to obtain the recombinant strains X-33-LF1-11-Lactoferricin-Lactoferrampin, X-33-LF1-11-Lactoferrampin-Lactoferricin, X-33-Lactoferricin-LF1-11-Lactoferrampin, X-33-Lactoferricin-Lactoferrampin-LF1-11, X-33-Lactoferrampin-LF1-11-Lactoferricin, and X-33-Lactoferrampin-Lactoferricin-LF1-11. The Oxford cup method was used to verify the inhibitory activity of the samples fermented by the above strains against Staphylococcus aureus. Figure 5 As shown, 1 is the fermentation product of X-33-LF1-11-Lactoferricin-Lactoferrampin, with an inhibition zone diameter of 8 mm, 2 is the fermentation product of X-33-LF1-11-Lactoferrampin-Lactoferricin, with an inhibition zone diameter of 10 mm, 3 is the fermentation product of X-33-Lactoferricin-LF1-11-Lactoferrampin, with an inhibition zone diameter of 21 mm, and 4 is the fermentation product of X-33-Lactoferricin-Lactoferricin. The diameter of the inhibition zone of errampin-LF1-11 fermentation product is 8mm, 5 is the fermentation product of X-33-Lactoferrampin-LF1-11-Lactoferricin, the diameter of the inhibition zone is 14mm, 6 is the fermentation product of X-33-Lactoferrampin-Lactoferricin-LF1-11, the diameter of the inhibition zone is 12mm, Lactoferricin is the fermentation product of X-33-Lactoferricin, the diameter of the inhibition zone is 18mm, and the outer diameter of the Oxford cup is 8mm. Under the same fermentation conditions, the strain X-33-Lactoferricin-LF1-11-Lactoferrampin has the best antibacterial effect.
[0064] Example 7: Determination of antibacterial activity of mutant peptides
[0065] The purified fermentation product of X-33-pPICZaA strain was used as a negative control, and the fermentation products of purified recombinant Pichia pastoris strains X-33-Lactoferricin, X-33-LFT1, X-33-LFT2, X-33-LFT3 and X-33-LFT4 were used to verify the antibacterial activity of the fermented samples against Staphylococcus aureus using the Oxford cup method. Figure 6As shown, Lactoferricin is the fermentation product of X-33-Lactoferricin, with an inhibition zone diameter of 18 mm, LFT1 is the fermentation product of X-33-LFT1, with an inhibition zone diameter of 17 mm, LFT2 is the fermentation product of X-33-LFT2, with an inhibition zone diameter of 17 mm, LFT3 is the fermentation product of X-33-LFT3, with an inhibition zone diameter of 22 mm, LFT4 is the fermentation product of X-33-LFT4, with an inhibition zone diameter of 12 mm, and X-33 is the fermentation product of X-33-pICZaA, with an inhibition zone diameter of 8 mm. Among them, LFT3 has the best antibacterial activity, which is 149% of Lactoferricin.
[0066] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A modified antimicrobial peptide, It is characterized in that The antimicrobial peptide modification is obtained by modifying the bovine lactoferricin antimicrobial peptide Lactoferricin, wherein the modification comprises fusion expression of the bovine lactoferricin antimicrobial peptide Lactoferricin with the bovine lactoferricin antimicrobial peptide LF1-11 and Lactoferrampin, or mutation of the bovine lactoferricin antimicrobial peptide Lactoferricin, wherein the mutant has any of the following mutations relative to the amino acid sequence shown in SEQ ID NO.6: (1) Arginine at position 4 mutated to glycine, arginine at position 5 mutated to threonine, and arginine at position 9 mutated to isoleucine; (2) mutation of arginine at position 5 to lysine; (3) mutation of glycine at position 14 to arginine; (4) The tryptophan at position 8 mutated to arginine, and the lysine at position 11 mutated to tryptophan.
2. The antimicrobial peptide modification according to claim 1, Features: The fusion is to fuse the bovine lactoferrin antimicrobial peptide Lactoferricin to the N-terminus of the bovine lactoferrin antimicrobial peptide LF1-11, and to fuse the bovine lactoferrin antimicrobial peptide Lactoferrampin to the C-terminus of the bovine lactoferrin antimicrobial peptide LF1-11.
3. A gene encoding the antimicrobial peptide modification according to claim 1 or 2.
4. A recombinant Pichia pastoris, Features: The antimicrobial peptide modification according to claim 1 or 2 is heterologously expressed in a Pichia pastoris host bacterium to obtain the recombinant Pichia pastoris.
5. The recombinant Pichia pastoris according to claim 4, Features: The Pichia pastoris host bacteria include Pichia pastoris X-33, Pichia pastoris GS115, Pichia pastoris SMD1168 or Pichia pastoris SMD1163.
6. The recombinant Pichia pastoris according to claim 4, Features: An inducible promoter is used to express the antimicrobial peptide modification.
7. The recombinant Pichia pastoris according to claim 6, Features: The inducible promoter includes P AOX1 Promoter.
8. The recombinant Pichia pastoris according to claim 4, Features: The antimicrobial peptide modification is secreted under the guidance of the signal peptide 0030-α, and the nucleotide sequence of the signal peptide 0030-α is shown in SEQ ID NO.
5.
9. A method for producing an antimicrobial peptide modification, Features: The method comprises the steps of fermenting and producing by using the recombinant Pichia yeast described in any one of claims 4 to 8.
10. The method according to claim 9, Features: The recombinant Pichia pastoris is inoculated into a fermentation medium for fermentation to obtain a fermentation broth, the bacterial cells are collected and washed, and then inoculated into an induction medium for induced expression of the antimicrobial peptide modified body.
11. The method according to claim 10, Features: The induction medium contains an inducer, and the final concentration of the inducer is 0.8-1.2%.
12. The method according to claim 10, Features: The fermentation medium comprises 18-22 g / L of peptone, 8-12 g / L of yeast powder, 8-12 mL / L of glycerol, 10-15 g / L of YNB, 3-5×10 -4 g / L, potassium phosphate buffer 80-120mM.
13. The method according to claim 10, Features: The induction medium comprises 18-22 g / L of peptone, 8-12 g / L of yeast powder, 4-7 mL / L of inducer, 10-15 g / L of YNB, 3-5×10 -4 g / L, potassium phosphate buffer 80-120mM.
14. Use of the modified antimicrobial peptide according to claim 1 or 2 or the recombinant Pichia pastoris according to any one of claims 4 to 8 in the preparation of a product having activity to inhibit Staphylococcus aureus.
Citation Information
Cited By
Signal peptides suitable for yeast and uses thereof
CN119930758A
Signal peptides suitable for yeast and uses thereof
CN119930758B
Product, system and method of cell cultivation
US12668774B2
Culture media based on protein hydrolysate and a process for preparing thereof
US12686847B2
Pet food, methods and devices for producing pet food
US12772996B2
